Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHow the dose schedule actually shapes your results, and the decision you're really making
The decision: oral tablet or weekly injection, and what the dose ladder tells you
Most people asking about the oral semaglutide dose are quietly asking a different question: is the tablet going to work as well as the injection? That is a fair thing to wonder. The maintenance dose of 25mg (daily tablet) and 2.4mg (weekly injection) both act on the same GLP-1 receptor, but oral semaglutide is absorbed less efficiently through the gut wall, which is why the tablet dose looks so much higher in milligrams. The absorption enhancer in the tablet (called SNAC) helps semaglutide cross the stomach lining, but the window for absorption is narrow. You need to take the tablet first thing, with no more than a small sip of plain water, and wait at least 30 minutes before eating, drinking coffee or taking other medicines. Miss that window and a meaningful portion of the dose is lost.
That requirement trips people up more than expected. It is not complicated, but it is strict, and the 13.6% average weight loss figure in the OASIS 4 trial captures everyone, including those whose routine made the 30-minute window harder to maintain consistently. The ~17% figure applies only to participants classified as fully adherent. If your mornings are genuinely chaotic, that distinction matters when you are deciding which format to discuss with a prescriber. You can read more about how the oral semaglutide dose compares across the licensed weight-loss schedule in our dedicated overview.
Neither number is a promise. Trial participants also received lifestyle support alongside treatment, and results varied individually. A prescriber looks at your full picture (weight history, other medicines, daily routine) before recommending a format or a starting point.
What each dose stage is actually doing
The 1.5mg starting dose exists to let your digestive system adjust. Nausea, loose stools and indigestion are the most commonly reported side effects of oral semaglutide, and they are most likely in the first weeks or after a dose increase. Starting low gives the body time to settle; it is not the dose at which most people notice meaningful appetite change. Think of it as calibration, not treatment in full effect.
The steps to 4mg and 9mg are where appetite suppression tends to become more noticeable for most people. GLP-1 agonists slow gastric emptying and act on satiety signals in the brain, so meals feel filling sooner and cravings between meals tend to quieten. The 9mg stage is held for at least a month before any move to 25mg, and the prescriber decides whether that move is appropriate, it is not automatic.
At 25mg maintenance, the trial evidence suggests weight loss continues for the duration of treatment, with the steepest reduction in the first half of the 64-week study period and a plateau as the body adjusts. The dose-by-dose breakdown for semaglutide tablets covers the clinical reasoning behind each step in more detail. For questions about how the full titration schedule looks in practice, the semaglutide oral dosage guide is the place to go.
One misconception worth clearing up gently: some readers arrive expecting the lower doses to be ineffective and want to skip ahead. Prescribers do not allow this, and for good reason. Rushing the schedule significantly increases the likelihood of side effects serious enough to interrupt treatment altogether. The ramp exists to protect the result.
What the OASIS 4 evidence does (and does not) tell us
The OASIS 4 trial enrolled 307 adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes. Participants took either oral semaglutide or a placebo for 64 weeks alongside lifestyle changes. The semaglutide group lost an average of 13.6% of body weight; the placebo group lost around 2.4%. Among those who maintained full adherence, the semaglutide average reached roughly 16.6%, which our Wegovy tablets overview rounds to approximately 17% with the mandatory framing that this applies to fully-adherent participants only.
The trial was funded by Novo Nordisk and formed part of the evidence base reviewed by the MHRA ahead of UK approval on 11 June 2026. The UK was the first country in Europe to approve an oral GLP-1 for weight management, that is a meaningful regulatory milestone, though it does not override individual clinical assessment. The MHRA approval announcement is the primary UK regulatory source for Wegovy approvals, and the NHS medicines pages carry patient-level detail on semaglutide side effects and what to watch for.
What the trial cannot tell you is how you specifically will respond. Weight loss with GLP-1 medicines varies considerably between individuals. Some people on the maintenance dose lose considerably more than the trial average; others less. The honest answer is that the dose schedule is the same for everyone, but the result is not.
How eligibility and your next step work in practice
The oral Wegovy tablet is licensed for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The tablet is not available on the NHS at launch (a NICE appraisal would be required first) so access currently means a private prescription following clinical assessment.
At nume, every consultation is read by a GPhC-registered Independent Prescriber, not automated software, the same day it is submitted. If you want to understand what oral semaglutide dosing means for your individual starting point, or you are curious about which tablet strengths form the licensed weight-loss schedule versus those used in diabetes treatment, both pages are worth reading before you consult. For a broader look at all licensed weight-loss treatments and how they compare, our weight-loss treatment overview covers the landscape clearly. When you are ready, start your free consultation and a prescriber will assess whether the oral tablet is the right fit for you.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.